SanaCurrents Portfolio Update: APLS files NDA, IMUX UC drug falters in phase II topline, plus VERA and ACET
Apellis Pharmaceuticals (NASDAQ:APLS) on June 1 submitted an NDA for its drug pegcetacoplan to be approved to treat geographic atrophy [...]
SanaCurrents capturing gain after Spectrum’s (SPPI) PDUFA catalyst up 92%; closing out BioXcel (BTAI)
Since SanaCurrents issued a report on Spectrum Pharmaceuticals’ (SPPI) cancer drug poziotinib on February 25, the company’s stock price has climbed 92%, closing [...]
Amryt receives CRL from the FDA; SanaCurrents closing coverage
UK-based Amryt Pharma plc (NASDAQ:AMYT) said before the market opened on February 28 it had received a complete response letter [...]
Immunocore (IMCR) Gains FDA Approval For Tebentafusp In Uveal Melanoma; SanaCurrents Closing Coverage
UK-based Immunocore Holdings plc (NASDAQ:IMCR) said on January 26 before the markets opened the FDA had approved the company’s biologic [...]
SanaCurrents Closed Coverage of Annexon (ANNX) on Conflicting Phase II Interim Data in Huntington’s Disease
When SanaCurrents issued its report on October 30, 2020, Annexon’s stock closed at $20.81 per share. The stock reached a high of $33.89 per share in March 2021 before leveling to a $20 to $22 per share range between May and mid-October. Annexon began to feel the biotech pull back in the latter months of last year, dropping to slightly more than $10 per share.
Portfolio Update: Closing out ARCT, BTCY, MRNS, KRON, AFIB; new approach to PDUFA catalysts
As noted in November 2021, Arcturus Therapeutics (NASDAQ:ARCT) was at the forefront of the Covid19 pandemic, teaming up in January [...]
Calliditas’ (CALT) IgAN drug gains FDA approval; SanaCurrents closing out coverage
After the markets closed on December 15, Calliditas Therapeutics said the FDA granted accelerated approval to TARPEYO (budesonide), formerly named [...]
Codiak (CDAK) to report early exoSTING data; SanaCurrents closing coverage
When SanaCurrents issued a March 19 report forecasting a positive outcome for Codiak Biosciences’ (NASDAQ:CDAK) phase I/II exoSTING trial, the favorable outlook was based [...]